FDA grants accelerated approval to Zongertinib for HER2-mutated non-squamous NSCLC
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
The hospital opens with 300 operational beds, including 100+ ICU beds and 5 advanced operating theatres
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
Facility designed to advance the next generation of imaging systems
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Subscribe To Our Newsletter & Stay Updated